The multi-part session, On Deck: Next Generation Biologics, was part of a larger session at the Transcatheter Cardiovascular Therapeutics (TCT) conference, called Strategies for Cardiovascular Repair: Stem Cells and Beyond. The first portion on extracellular matrices and related products was presented by Karen Christman, PhD, associate professor of bioengineering at the University of California San Diego. Dr Christman discussed the use biomaterials for treating the extracellular matrix of the heart after MI.
The multi-part session, “On Deck: Next Generation Biologics,” was part of a larger session at the Transcatheter Cardiovascular Therapeutics (TCT) conference, called “Strategies for Cardiovascular Repair: Stem Cells and Beyond.” The first portion on extracellular matrices and related products was presented by Karen Christman, PhD, associate professor of bioengineering at the University of California San Diego. Dr Christman discussed the use biomaterials for treating the extracellular matrix of the heart after MI. This matrix provides structural framework and important biochemical cues that can be used to direct repair and regeneration. She discussed 2 different methods of biomaterial delivery: an epicardial patch and an injectable material. By recreating the structural framework, endogenous cells will repopulate the area of infarct and help repair it. Dr Christman and colleagues developed a form of native cardiac extracellular matrix from porcine ventricles that can be delivered via catheter to the heart. Rodent studies have shown that after delivery, there is reassembly of the scaffold and recruitment of cells into the area for up to 3 weeks. They have also demonstrated that this results in improved global and regional cardiac function, decreased collagen (scar) formation, and increased myocardial matrix and endocardial muscle.
The second portion, called “Small Molecules and mi-RNAs,” was delivered by Stefanie Dimmeler, PhD, director of the Institute of Cardiovascular Regeneration at the University of Frankfurt in Germany. Dr Dimmeler began by explaining that microRNAs, roughly 22 nucleotides long, can result in mRNA degradation or translational repression. By modulating pathways, they can change expression of a network of genes, not just a single gene. microRNAs can also be used as biomarkers of disease. Several of them are known to control or enhance angiogenesis, cardiac reprogramming, and cardiomyocyte proliferation. In particular, miR-92a has been shown to block angiogenic sprouting in vitro and in model organisms. It is expressed in vessels and cardiomyocytes. Dr Dimmeler and team then studied the effects of antagomir-92a and LNA-92a, which block expression of miR-92a in animal hearts. It was shown that antagomir-92 improves myocardial recovery after ischemia. Additionally, local delivery of LNA-92a demonstrated inhibition of miR-92a expression in non-infarct as well as infarcted regions of the heart and reduced the infarct size. Local delivery was more effective than IV delivery in improvement of global function. It is thought that the mechanism is significant improvement in capillary density and decrease in cardiac muscle cell death. Inflammation was also significantly reduced in the infarcted tissue. In summary, the short-term inhibition of miR-92a improved the recovery of cardiac function after ischemia in mice and pigs.
“Induced Pluripotent Cells” was the final presentation of the session, given by Joseph C. Wu, MD, PhD, professor of medicine and director of the Stanford Cardiovascular Institute at Stanford School of Medicine. Dr Wu described 3 cardiac applications of induced pluripotent cells (iPSCs). The first is disease modeling; he gave examples of how iPSCs are helping us to understand the molecular mechanisms of hypertrophic and dilated cardiomyopathies. The second application is drug discovery and pharmacogenomics. The third is cell therapy, either autologous or allogeneic. He stated that this field is moving very quickly, and several human iPSC trials are currently planned. In fact, a group in Japan is now recruiting patients for a study to evaluate autologous iPSC injections in patients with macular degeneration.
ATS 2024: Bridging the Past, Present, and Future of Respiratory Care
May 16th 2024The application of artificial intelligence in medicine is anticipated as a highlight of ATS 2024, with sessions exploring its applications in research, radiological interpretation, and pediatric pulmonology.
Read More
The Importance of Examining and Preventing Atrial Fibrillation
August 29th 2023At this year’s American Society for Preventive Cardiology Congress on CVD Prevention, Emelia J. Benjamin, MD, ScM, delivered the Honorary Fellow Award Lecture, “The Imperative to Focus on the Prevention of Atrial Fibrillation,” as the recipient of this year’s Honorary Fellow of the American Society for Preventive Cardiology award.
Listen
Looking Back on ISPOR 2024: Hot Policy Topics, Welcome Focus on Employers, and More
May 10th 2024Kimberly Westrich, MA, chief strategy officer of the National Pharmaceutical Council, reflects on the most valuable learnings from the 2024 meeting of ISPOR—The Professional Society for Health Economics and Outcomes Research, including lively discussions of the Inflation Reduction Act and workshops on value assessment.
Read More
Promoting Equity in Public Health: Policy, Investment, and Community Engagement Solutions
June 28th 2022On this episode of Managed Care Cast, we speak with Georges C. Benjamin, MD, executive director of the American Public Health Association, on the core takeaways of his keynote session at AHIP 2022 on public health policy and other solutions to promote equitable health and well-being.
Listen
Posters Characterize DMD Caregiver Experiences, Impact of Gene Therapy on Caregiving Demands
May 10th 2024Posters presented at the ISPOR—The Professional Society for Health Economics and Outcomes Research meeting explored Duchenne muscular dystrophy (DMD) caregiver experiences and gene therapy’s impact on work opportunities for caregivers.
Read More
A Focus on Women: AUA Best Posters Highlight Female Athletes, Prenatal Care, and Women in Urology
May 9th 2024Three posters from the American Urological Association (AUA) 2024 Annual Meeting focused on urinary incontinence in female athletes, prenatal care for fetuses with spina bifida in California, and the experiences of women residents at the Brady Urological Institute.
Read More